Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045487 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Advanced Kidney Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00045487 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 41 participants.
The verdict
NCT00045487, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have advanced kidney cancer.
Interventions
- DRUG OSI-774
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2002-06 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045487
The ClinicalTrials.gov registry entry for NCT00045487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OSI-774 is the first listed.
NCT00045487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045487 about?
NCT00045487 is a clinical study titled "Erlotinib in Treating Patients With Advanced Kidney Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have advanced kidney cancer.
What is the current status of trial NCT00045487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2002-06. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00045487?
The interventions under investigation include: OSI-774 (DRUG).
Who is sponsoring clinical trial NCT00045487?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.